Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 18, 2026 08:36 ET | Source: AIM ImmunoTech Inc.

AIMイムノテック、アンプリジェンとチェックポイント阻害剤を併用する新規がん治療法の、日本における特許の最終承認を発表

フロリダ州オカラ発, March 18, 2026 (GLOBE NEWSWIRE) -- AIMイムノテック (AIM ImmunoTech Inc.) (NYSE American：AIM) (「AIM」または「同社」) は本日、日本特許庁が同社独自のアンプリジェン (Ampligen) (リンタトリモド) とチェックポイント阻害剤 (抗PD-1抗体または抗PD-L1抗体)...
March 18, 2026 08:36 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese patent...
March 06, 2026 19:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Closing of its Rights Offering

OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...
March 04, 2026 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million

OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...
March 02, 2026 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo...
February 27, 2026 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...
February 25, 2026 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026

OCALA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...
February 23, 2026 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer

OCALA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced milestones in the expected timeline for the ongoing Phase 2 clinical...
February 12, 2026 16:35 ET | Source: AIM ImmunoTech Inc.

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on...
February 12, 2026 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, February 19th at 4:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer ...